Session 123 - CROI 2008

Home

Session 123 Poster Abstracts
ART: Novel Approaches I
Tuesday, 1-4 pm
Room: Hall A

726a	Biochemical Mechanism of HIV-1 Reverse Transcriptase Inhibition and Resistance to Translocation-deficient RT Inhibitors Bruno Marchand*¹, L Michailidis¹, A Fopoussi¹, E Kodama², M Matsuoka², N Ashida³, E Nagy⁴, M Parniak⁴, H Mitsuya^5,6, and S Sarafianos¹ ¹Univ of Missouri, Columbia, US; ²Kyoto Univ, Japan; ³Yamasa Corp, Chiba, Japan; ⁴Univ of Pittsburgh, PA, US; ⁵Kumamoto Univ, Japan; and ⁶NIH, Bethesda, MD, US
726b	Drug Susceptibility Profile of OBP-601, a Novel NRTI, Using a Comprehensive Panel of NRTI- or NNRTI-resistant Viruses Jan Weber*¹, J Weberova¹, A Vazquez¹, Y Urata², T Matsuda², R Shafer³, E Arts⁴, and M Quinones-Mateu¹ ¹Diagnostic Hybrids Inc, Cleveland, OH, US; ²Oncolys BioPharma, Tokyo, Japan; ³Stanford Univ, Palo Alto, CA, US; and ⁴Case Western Reserve Univ, Cleveland, OH, US
727	Antiviral and Pharmacokinetic Properties of 3’-Azido-2’,3’-Dideoxypurines that Exhibit Potent Activity against Drug-resistant HIV-1 Nicolas Sluis-Cremer*¹, D Koontz¹, B Hernandez-Santiago², K Rapp², F Amblard², L Bondada², S Coats³, R Schinazi², and J Mellors¹ ¹Univ of Pittsburgh Sch of Med, PA, US; ²Emory Univ and VAMC, Decatur, GA, US; and ³RFS Pharma, LLC, Tucker, GA, US
728	Characterization of a NNRTI, UK-453,061 in vitro Julie Mori*¹, R Corbau¹, D Lewis², S Ellery², H Mayer², M Perros¹, and M Westby¹ ¹Pfizer Global R&D, Sandwich Labs, Kent, UK and ²Pfizer Global R&D, New London, CT, US
729	Genotypic Resistance and Phenotypic Cross-resistance Profile in vitro for a Novel NNRTI: IDX899 Douglas Richman*¹, J Jakubik², C Chapron², L Hubbard², L Gray², M Seifer², and D Standring² ¹Univ of California, San Diego and VA San Diego Hlthcare System, US and ²Idenix Pharma, Inc, Cambridge, MA, US
730	RDEA427 and RDEA640 Are Novel NNRTI with Potent Anti-HIV Activity against NNRTI-resistant Viruses Anneke Raney*, R Hamatake, W Xu, J M Vernier, J L Girardet, P Weingarten, and B Quart Ardea Biosci, Inc, San Diego, CA, US
731	An IQ Assessment of RDEA806, a Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins Robert Hamatake*, W Xu, A Raney, J L Girardet, M Nguyen, L T Yeh, and B Quart Ardea Biosci, Inc, San Diego, CA, US
732	GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Peripheral Glucose Disposal in a Healthy Rodent Model System Christian Callebaut*¹, Q Yan², J Koster², L Tsai¹, T Cihlar¹, and P Hruz² ¹Gilead Sci, Foster City CA, US and ²Washington Univ Sch of Med, St Louis, MO, US
733	Non-peptidyl Small Molecule Protease Dimerization Inhibitors: Molecular and Structural Analysis of Their HIV-1 Inhibition and Interactions with Protease Monomer Subunit Yasuhiro Koh*¹, D Das², M Amano¹, D Davis², J Li³, S Leschenko³, A Baldridge³, R Yarchoan², A Ghosh³, and H Mitsuya^1,2 ¹Kumamoto Univ Sch of Med, Japan; ²NCI, NIH, Bethesda, MD, US; and ³Purdue Univ, West Lafayette, IN, US
734	INH-I001, an HIV Integrase Inhibitor with Potent in vitro Anti-HIV Activity: Microsome and Cytosol Stability Studies, Cytochrome P450 Data and Pharmacokinetics Vasu Nair*¹, X Ma¹, C White¹, S Blue¹, G Chi¹, and J Patti² ¹Univ of Georgia, Athens, US and ²Inhibitex, Inc, Alpharetta, GA, US
735	Novel Treatment Strategies in HIV-1 Drug Discovery: Targeting the HIV-1 Integrase-LEDGF/p75 Interaction Frauke Christ*¹, H Langedijk², K Bartholomeeussen¹, and Z Debyser¹ ¹KULeuven, Belgium and ²Pepscan Systems, Lelystad, The Netherlands
736	Induction in vitro of HIV-1 Variants Resistant to a Low-molecular CD4 Mimic Compound, N-(4-Chlorophenyl)-N’-(2,2,6,6-tetramethylpiperidin-4-yl)-oxalamide Kazuhisa Yoshimura*¹, J Shibata¹, A Honda¹, Y Yamada², H Masuno², H Tamamura², and S Matsushita¹ ¹Ctr for AIDS Res, Kumamoto Univ, Japan and ²Inst of Biomaterials and Bioengineering, Tokyo Med and Dental Univ, Japan
737	PF-232798, a Second Generation Oral CCR5 Antagonist Patrick Dorr*, M Westby, L McFadyen, J Davis, P Stupple, D Middleton, F Perruccio, R Jones, J Mori, and M Perros Pfizer, Sandwich, UK
738	ESN-196, a Novel, Small-molecule CCR5 Agonist Inhibits R5 HIV Infection 0 Ferain¹, D Schols², J Bernard¹, R Sleigh¹, F Ooms¹, J Huck¹, V Dupriez¹, and Graeme Fraser*¹ ¹Euroscreen SA, B-1070 Brussels and B-6041 Gosselies, Belgium and ²Rega Inst for Med Res, KULeuven, Belgium
739	Potent CCR5 Inhibition by Fully Recombinant RANTES Analogs Requires Neither Internalization Nor Signaling Donald Mosier*¹, R Nedellec¹, J Salkowitz-Bokal¹, M Coetzer¹, M Lederman², R Offord³, and O Hartley³ ¹Scripps Res Inst, La Jolla, CA, US; ²Case Western Reserve Univ, Cleveland, OH, US; and ³Univ of Geneva, Switzerland
741	Peptide “Stapling” Dramatically Enhances the Biophysical Properties of HIV Fusion Inhibitors Gregory Bird*^1,2, N Madani^1,2, A Hubicki^1,2, J Sodroski^1,2, and L Walensky^1,2 ¹Dana-Farber Cancer Inst, Boston, MA, US and ²Harvard Med Sch, Boston, MA, US
742	Type I Interferons Vary in Their Ability to Inhibit HIV Replication in Primary Macrophages S H Wie¹, S Rought², P Du², D Richman², and Christopher Woelk*² ¹Catholic Univ of Korea, Seoul, South Korea and ²Univ of California, San Diego, US